I see a lot of carefully curated portfolios crossing my desk, but this one is a true Frankenstein’s monster of market leftovers. We’ve got a grab bag of unclassified tickers thrown together—from AI infrastructure and obesity drugs to a defense landlord and an ethical egg farmer. This is stupid and here's why: trying to find a unified macro thesis here is a fool's errand. But if you look closely, this bizarre cross-section reveals exactly what's wrong—and right—with the market in 2026. The boring companies are printing cash, while the ones spinning massive narratives are burning it at record speed.

The Cash Burners: TROOPS INC (TROO.US) & EOS ENERGY (EOSER.US)

Let's start with the pivoters. TROOPS INC is a Hong Kong-based conglomerate attempting to morph into a real estate and fintech player. The stock has been languishing lately, which is hardly surprising. With a recent Hong Kong court ordering them to cough up HKD 404 million in judgments, their recent talk of buying a massive UK property portfolio sounds a lot more like an escape hatch than a coherent growth strategy. Then we have Eos Energy. They managed to pull in USD 114.2 million in total revenue in 2025, but somehow posted a staggering net loss of USD 969.6 million. Now they are aggressively pivoting to power AI data centers with their zinc batteries, which has predictably given their shares a speculative pop recently. Everyone is playing the AI infrastructure card right now to distract from terrible margins. Burning almost a billion dollars while trying to blindly catch the AI wave? Good luck with that.

The Profit Machines: VERISIGN (VRSN.US) & VITAL FARMS (VITL.US)

You want to know what actually makes money? Internet monopolies and chickens. Verisign is a ruthless tollbooth on the web. They just announced they are jacking up the price of a .com domain yet again, this time to USD 10.97. What are you going to do, not have a website? The stock has remained steady as a rock, and they quietly pocketed USD 215 million in net income in Q1 2026. On the completely opposite end of the spectrum is Vital Farms, which recently saw its shares under some pressure despite posting a very healthy USD 187.2 million in Q1 total revenue. In a market totally obsessed with generative AI vaporware, selling ethically sourced, pasture-raised eggs is a refreshingly real business. Why aren't more tech founders just making things people actually need instead of solving imaginary problems?

The Financial Opportunists: ENOVA (ENVA.US) & TRINITY CAPITAL (TRIN.US)

Over in fintech, Enova International is absolutely crushing it. The stock just hit a 52-week high because their machine-learning-driven lending model is actually delivering real-world results. Total revenue jumped 17% in Q1 2026 to USD 875 million. Meanwhile, Trinity Capital is stepping right into the massive void left by terrified traditional banks. Shares have surged over 30% this year, and they confidently locked in USD 1.1 billion in new commitments in the first half of 2026. This is exactly what happens when legacy banking gets complacent and tightens the purse strings unnecessarily—alternative capital simply swoops in and eats their lunch.

The Hopefuls: METAVIA (MTVA.US) & COPT DEFENSE (CDP.US)

MetaVia is a clinical-stage biotech desperately trying to get in on the obesity and MASH drug gold rush. Listen, every biotech CEO on the planet wants to be the next Ozempic billionaire, but MetaVia is sitting on just USD 13.7 million in cash as of Q1 2026, which barely keeps the lights on through the end of the year. The stock has been struggling lately because the clock is loudly ticking. If you don't have billions in backing, you can't even buy a ticket to this particular circus. On the safer side, COPT Defense Properties is quietly leasing secure buildings to the US government. JPMorgan just scooped up over 1.16 million shares. It is incredibly boring, the stock action is entirely muted, but it pays the bills consistently without any of the Silicon Valley drama.

The Tools: XPP (XPP.US) & AIQU (AIQU.US)

Finally, we have the pure speculative instruments. ProShares Ultra FTSE China 50 (XPP) and AIQU give day traders a high-octane way to gamble on 50 large-cap Chinese names or a leveraged basket of AI concepts. They swing wildly with every macro headline. Grouping these volatile trading vehicles with real operating companies is peak Wall Street absurdity. Ultimately, do not let the shiny ticker symbols fool you. I would rather bet my money on a ruthless domain registry or a profitable egg farm than most of these heavily leveraged tech narratives.

This article does not constitute investment advice.